Promoted Content
Promoted Content

Find Gastroenterology Drugs in Phase I Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRA023

            Therapeutic Area: Gastroenterology Product Name: PRA023

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: SVB Leerink

            Deal Size: $190.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering March 11, 2021

            Details:

            Prometheus' lead candidate PRA023 is an IgG1 humanized mAb that has been shown to block TL1A. PRA023 binds both soluble and membrane-associated human TL1A with high affinity and specificity to substantially improve outcomes for moderate-to-severe IBD patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRA023

            Therapeutic Area: Gastroenterology Product Name: PRA023

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Celerion

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2021

            Details:

            PRA023, the company's lead product candidate, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Olanzapine

            Therapeutic Area: Gastroenterology Product Name: STAR-OLZ

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Haisco Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 01, 2021

            Details:

            Under the terms of the agreement, Starton will receive an undisclosed upfront cash payment and is eligible to receive additional development and regulatory milestone payments, plus double-digit royalties on annual net sales of STAR-OLZ in the territory.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MORF-057

            Therapeutic Area: Gastroenterology Product Name: MORF-057

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 01, 2021

            Details:

            In the Phase 1 SAD trial, MORF-057 was well tolerated in all 5 cohorts receiving MORF-057 in single doses ranging from 25 mg to 400 mg with no serious adverse events (SAEs) and no significant lab abnormalities in any subject.